Pharmaceutical R&D investment and cash flows: An instrumental variables approach to testing for capital market imperfections

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 13, Issue 4, 2004, Pages 3-17

  Vernon, John A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Capital market imperfections; Cash flows; Pharmaceutical R D

Indexed keywords

CAPITAL; COST; DEVELOPMENT; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; INVESTMENT; MARKET; MODEL; PHARMACY; POLICY; PRIORITY JOURNAL; RESEARCH; REVIEW;

EID: 23944456481     PISSN: 15385698     EISSN: None     Source Type: Journal    
DOI: 10.1300/J371v13n04_02     Document Type: Review

References (15)

1. Bhattacharya, Sudipto and Ritter, Jay R. (1985) "Innovation and Communication: Signalling with Partial Disclosure." Review of Economic Studies L: 331-46.
2. Grabowski, Henry G. (1968) "The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries." Journal of Political Economy, 76(2):292-306.
3. Grabowski, H.G. and Vernon, J.M. (1981) "The Determinants of R&D Expenditures in the Pharmaceutical Industry," in Robert Helms, ed., Drugs and Health. 3-20 (Washington. DC: AEI Press).
4. Grabowski, H.G. and Vernon. J.M. (1997) "The Search for New Vaccines: The Effects of the Vaccines for Children Program" (Washington, DC: AEI).
5. Grabowski, H.G. and Vernon. J.M. (2000) "The Determinants of Pharmaceutical Research and Development Expenditures." Journal of Evolutionary Economics, 10: 201-215.
6. Hall, Bronwyn H. (1992) "Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?" NBER Working Papers, Working Paper No. 4096, NBER.
7. Hubbard, G. (1998) "Capital Market Imperfections and Investment." Journal of Economic Literature, vol. XXXVI (March): 193-225.
8. Kihlstrom. Richard and Matthews, Steve (1984) "Managerial Incentives in Publicly Traded Firms." University of Pennsylvania Working Paper.
9. Leland, Hayne E. and Pyle. David H. (1977) "Informational Asymmetries. Financial Structure, and Financial Intermediation" Journal of Finance 32: 371-387.
10. Maddala. G.S. (2001) "Introduction to Econometrics," Third Edition, Wiley & Sons, Ltd.
11. Modigliani, F. and Miller. M. (1958) "The Cost of Capital, Corporation Finance and the Theory of Investment," American Economic Review, 48(3):261-297.
12. Murphy. K. and Topel, R. (2003) "Measuring the Gains from Medical Research," University of Chicago Press.
13. Nicholson, S., Danzon. P. and McCullough, J. (2002) "Biotech- Pharmaceutical Alliances as a Signal of Asset and Firm." University of Pennsylvania Working Paper.
14. Vernon, J.A. (2003) "The Relationship Between Price Regulation and Pharmaceutical Profit Margins." Applied Economics Letters. 10: 467-470.
15. Vernon, J.A. (2004) "Examining the Link Between Price Regulation and Pharmaceutical R&D Investment." Health Economics. 14(1): 1-16.